Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation; the role of plerixafor.
Kosmas C, Kranidioti E, Kosma A, Karakosta M, Miltiadous C, Grivas A, Athanasopoulos A, Lianos E. Kosmas C, et al. Among authors: miltiadous c. Leuk Lymphoma. 2019 Jul;60(7):1819-1822. doi: 10.1080/10428194.2018.1543879. Epub 2019 Jan 8. Leuk Lymphoma. 2019. PMID: 30618317 No abstract available.
Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E, Assi A, Kranidioti E, Kosma A, Karakosta M, Miltiadous C, Dimitriadis GK, Grivas A, Athanasopoulos A, Lianos E, Kosmas C. Fergadis E, et al. Among authors: miltiadous c. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e50-e57. doi: 10.1016/j.clml.2019.11.022. Epub 2019 Dec 6. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31884151
Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
Kosmas C, Athanasopoulos A, Dimitriadis G, Miltiadous C, Zilakos M, Lydakis D, Magiorkinis E, Gekas C, Daladimos T, Mylonakis N, Ziras N. Kosmas C, et al. Among authors: miltiadous c. Anticancer Drugs. 2014 Aug;25(7):841-7. doi: 10.1097/CAD.0000000000000100. Anticancer Drugs. 2014. PMID: 24625457